Nama's AI scorecard currently rates Novavax Sell (3.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does NVAX report earnings?

Novavax's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.58.

What is the NVAX price target?

The median analyst price target from 9 analysts is $16.00, with a range of $7.00 – $25.00.

Is NVAX Shariah compliant?

Nama's AAOIFI-style screen reads Novavax as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Novavax (NVAX)

Healthcare · Biotechnology · NASDAQ

Novavax (NVAX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.78B and a free-cash-flow yield of -13.4%. Over the most recent reported fiscal year, revenue grew 64.7%. Nama's AI scorecard rates it Sell, 3.3 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 3.3/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Rising · +47.8% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-95.4%

How far the last close sits under the highest price of the past five years.

Market cap	$1.78B
Trailing P/E	—
Price / book	—
Price / sales	4.3
FCF yield	-13.4%
Dividend yield	—
Gross margin	78.6%
Operating margin	-32.9%
Net margin	-59.9%
Revenue growth (YoY)	+64.7%
Revenue growth (3-yr annual)	-11.1%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	2.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

NVAX earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.58). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	-$0.19	-$0.35	+45.7%	—
Q2 2026	Aug 6, 2026	-$0.32	-$0.38	+15.8%	$56.70M
Q1 2026	May 6, 2026	-$0.06	-$0.37	+83.8%	$139.51M
Q4 2025	Feb 26, 2026	$0.11	-$0.55	+120.0%	$147.14M

NVAX analyst price target

Median target $16.00 from 9 analysts, ranging $7.00 – $25.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live NVAX data on Nama Insights →

Recent Congressional trades

Novavax trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Pat Roberts	Senate	Sell	$1,001 - $15,000	—
Pat Roberts	Senate	Buy	$1,001 - $15,000	—

NVAX FAQ

Is NVAX a buy?: Nama's AI scorecard currently rates Novavax Sell (3.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does NVAX report earnings?: Novavax's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.58.
What is the NVAX price target?: The median analyst price target from 9 analysts is $16.00, with a range of $7.00 – $25.00.
Is NVAX Shariah compliant?: Nama's AAOIFI-style screen reads Novavax as Not Shariah Compliant. At least one of the three ratios or the industry test failed.